Donpezil efficacy in prevention of cognitive impairment induced by electroconvulsivetherapy

Evaluation of Donepezil effectiveness on prevention of cognitive impairment caused by electroconvulsivetherapy (ECT) in mood disorder patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180623040193N1

Enrollment

Registered

2018-07-09

Start date

2017-06-22

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment.

Interventions

Intervention 1: Intervention group: consumption of 5 mg per day of Donepezi(Produced in Ramofarmin Pharmaceutical Company) before the start of electrocunvulsivetherapy to one month after the end of i

Eligibility

Sex/Gender

All

Age

15 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 15-65 years old Diagnosis of Major depressive disorder by a psychiatrist Diagnosis of bipolar disorder by a psychiatrist Prescribing at least four session of elecctroconvulsivetherapy inform consent

Exclusion criteria

Exclusion criteria: Dissatisfaction for continued study Mental retardation dementia discontinue treatment before session 4 Delirium during treatment Prohibition of acetyl cholinesterase inhibitors because of a cardiac disorder chronic obstructive pulmonary disease Acute peptic ulcer Lack of literacy

Design outcomes

Primary

Measure	Time frame
Cognitive impairment. Timepoint: before start of electroconvulsivetherapy, before session 4 and one month after the end of electroconvulsivetherapy. Method of measurement: Addenbrooke’s Cognitive Examination-C, mini mental status examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Zarean

Shahre-kord University of Medical Sciences

ezarean@gmail.com+98 38 3222 0016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026